Identification

Name
Pitolisant
Accession Number
DB11642
Type
Small Molecule
Groups
Approved, Investigational
Description

Pitolisant is also known as 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine or BF2.649 [4]. It is a selective inverse agonist of the histamine H3 receptor that is used in the treatment of type 1 or 2 narcolepsy with or without cataplexy in adults. Narcolepsy is a chronic neurological disorder that that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations [4]. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotion [1]. As histaminergic signalling in neurons plays a role in maintaining wakefulness, pitolisant works by blocking histamine autoreceptors and enhancing the activity of brain histaminergic neurons [5].

In a European clinical trial of adult patients with narcolepsy, a reduction in the Epworth Sleepiness Scale (ESS) score was observed from pitolisant treatment compared to placebo [3]. The therapeutic effectiveness of pitolisant was comparable to that of Modafinil [3]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency [2]. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms [2], however the safety of use in adolescent or paediatric patients have not been established with pitolisant. Pitolisant is marketed by EMA under the trade name Wakix as oral tablets.

Structure
Thumb
Synonyms
Not Available
External IDs
BF-2.649 / BF-2649 / BF2.649
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
WakixTablet, film coated4.5 mgOralBioprojet Pharma2016-03-31Not applicableEu
WakixTablet, film coated18 mgOralBioprojet Pharma2016-03-31Not applicableEu
Categories
UNII
4BC83L4PIY
CAS number
362665-56-3
Weight
Average: 295.85
Monoisotopic: 295.1702922
Chemical Formula
C17H26ClNO
InChI Key
NNACHAUCXXVJSP-UHFFFAOYSA-N
InChI
InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2
IUPAC Name
1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine
SMILES
ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1

Pharmacology

Indication

Indicated in adults for the treatment of narcolepsy with or without cataplexy [5].

Associated Conditions
Pharmacodynamics

In patients with narcolepsy in presence or absence of cataplexy, treatment of pitolisant was associated with an improvement in the level and duration of wakefulness and daytime alertness assessed by objective measures of ability to sustain wakefulness (e.g. Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) Scores) and attention (e.g. Sustained Attention to Response Task (SART)) [5]. Pitolisant also improved the frequency and severity of narcolepsy-associated cataplexy [1]. Pitolisant acts as a blocker at hERG channels. In two dedicated QT studies, supra-therapeutic doses of pitolisant (3-6-times the therapeutic dose, that is 108 mg to 216 mg) produced mild to moderate prolongation of QTc interval (10-13 ms) [5].

Mechanism of action

Pitolisant acts as a high-affinity competitive antagonist (Ki 0.16 nM) and as an inverse agonist (EC50 1.5 nM) at the human histamine H3 receptor subtype [1]. Signalling of histaminergic neurons plays a key role in activating the arousal system with widespread projections to the whole brain [5] via activating orexin receptors [1]. Narcolepsy is characterized by insufficient neurotransmission by orexins, or hypocretins, which are excitatory peptides released by aminergic neurons from the lateral hypothalamus with widespread projections [4]. H3 receptors are autoreceptors that promote the re-uptake of histamine at synaptic terminals and attenuate further histamine release into the synapse [4]. By blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse, pitolisant enhances the activity of brain histaminergic neurons and promotes wakefulness [5]. Inverse agonism of pitolisant at H3 receptors also leads to enhanced synthesis and release of endogenous histamine over the basal level [4].

Pitolisant is thought to bind to the antagonist binding site of H3 receptor, which is located within the trans-membrane core just below the extracellular loops. Piperidines forms a salt bridge with Glu206 in the membrane spanning segment and the hydroxyl of Tyr374 is H-bonded with the central oxygen of piperidine [4]. Pitolisant displays high selectivity for H3 receptors compared to other histamine receptor subtypes. Pitolisant also modulates acetylcholine, noradrenaline and dopamine release in the brain by increasing the levels of neurotransmitters but does not increase dopamine release in the stratal complex including nucleus accumbent [5].

TargetActionsOrganism
AHistamine H3 receptor
antagonist
inverse agonist
Human
NPotassium voltage-gated channel subfamily H member 2
blocker
Human
Absorption

Pitolisant is rapidly and well absorbed. Following oral administration of 20 mg in healthy individuals, the peak plasma concentration (Cmax) was approximately 30 ng/mL [4]. The Cmax is typically reached approximately 3 hours following administration [5]. Food intake significantly reduces the systemic exposure of pitolisant with a decrease in both AUC and Cmax [6]. Following repeated dosing, the steady-state plasma concentration is achieved after 5-6 days of administration leading to an increased serum level around 100% [5]. Inter individual variability is reported to be high [5]. The absolute bioavailability of pitolisant has not been determined [6].

Volume of distribution

Following single and multiple oral dosing of pitolisant to healthy male adults at doses between 1 and 240 mg, the apparent volume of distribution (V/F) ranges from 1100 to 2825 L [6]. Pitolisant is thought to be equally distributed between red blood cells and plasma [5]. Following intravenous administration of pitolisant in rats and monkeys, the apparent Vd at steady-state was approximately 10-fold greater than total body water [6]. Pitolisant crosses the blood-brain barrier and placenta, and was found in milk in rats [6].

Protein binding

Pitolisant exhibits high serum protein binding (>90%) [5].

Metabolism

Pitolisant undergoes hepatic CYP3A4- and CYP2D6-mediated metabolism to form major non-conjugated metabolites BP2.941 and BP2.951 , which are hydroxylated derivatives in several positions [5]. BP2.941 and BP2.951 can further be oxidized but oxidized metabolites of pitolisant such as BP1.2525 and BP1.2526 are only present to a minor extent [6]. Only BP1.2526 and BP1.2525 at a lesser extent have an affinity towards human H3 receptor [6]. The 5-aminovaleric acid is the major phase I inactive metabolite and is found in urine and serum, and its metabolism is mediated by CYP3A4 and CYP2D6 [5].

Several conjugated metabolites were also identified; the major conjugated inactive metabolite was a glycine conjugate of the acid metabolite of O-dealkylated desaturated pitolisant and a glucuronide of a ketone metabolite of monohydroxy desaturated pitolisant [5].

Route of elimination

Following hepatic metabolism, about 63% of total elimination occurs via renal excretion into the urine as an inactive non-conjugated metabolite BP2.951 and a glycine conjugated metabolite [5]. About 25% of the total dose administered is excreted through expired air as metabolites, and a small fraction (<3%) of drug can be recovered in faeces [5].

Half life

Pitolisant has a plasma half-life of 10-12 hours [5].

Clearance

The apparent clearance rate is expected to be lower with increasing age [6].

Toxicity

Symptoms of pitolisant overdose may include headache, insomnia, irritability, nausea and abdominal pain. In case of overdose, hospitalisation and monitoring of the vital functions are recommended. There is no clearly identified antidote [5].

After 1 month in mice, 6 months in rats and 9 months in monkeys, no adverse effect level (NOAEL) were 75, 30 and 12 mg/kg/day, p.o., respectively [5]. Pitolisant was not found to be genotoxic in Ames test nor carcinogenic in mouse and rat carcinogenicity studies [6]. In rabbit and rat teratogenicity studies, maternally high toxic doses of pitolisant sperm morphology abnormalities and decreased motility without any significant effect on fertility indexes in male rats [5]. It also decreased the percentage of live conceptuses and increased post-implantation loss in female rats [5]. A delay in post-natal development was observed [5].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pitolisant.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Pitolisant.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Pitolisant.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Pitolisant.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Pitolisant.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Pitolisant.Experimental, Illicit
AbemaciclibThe serum concentration of Abemaciclib can be decreased when it is combined with Pitolisant.Approved, Investigational
AbirateroneThe serum concentration of Pitolisant can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Pitolisant can be increased when it is combined with Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pitolisant.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Pitolisant.Approved, Experimental, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Pitolisant.Approved, Investigational
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Pitolisant.Approved
Acetyl sulfisoxazoleThe metabolism of Pitolisant can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Pitolisant.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Pitolisant.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pitolisant.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Pitolisant.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Pitolisant.Approved
AjmalineThe serum concentration of Pitolisant can be increased when it is combined with Ajmaline.Approved, Investigational
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Pitolisant.Approved, Vet Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pitolisant.Approved, Withdrawn
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Pitolisant.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Pitolisant.Experimental, Investigational
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Pitolisant.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Pitolisant.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Pitolisant.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Pitolisant.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Pitolisant.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pitolisant.Experimental
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Pitolisant.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Pitolisant.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Pitolisant.Approved, Withdrawn
alpha-Tocopherol acetateThe serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Pitolisant.Approved
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Pitolisant.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Pitolisant.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Pitolisant.Approved, Investigational
AmineptineThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Amineptine.Illicit, Withdrawn
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Pitolisant.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Pitolisant.Approved
AmiodaroneThe serum concentration of Pitolisant can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Pitolisant can be increased when it is combined with Amitriptyline.Approved
AmitriptylinoxideThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Amitriptylinoxide.Approved, Investigational
AmlodipineThe serum concentration of Pitolisant can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Pitolisant can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Amoxapine.Approved
AmphetamineThe serum concentration of Pitolisant can be increased when it is combined with Amphetamine.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Pitolisant.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Pitolisant.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Pitolisant.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pitolisant.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pitolisant.Investigational
AntipyrineThe serum concentration of Pitolisant can be increased when it is combined with Antipyrine.Approved, Investigational
ApalutamideThe serum concentration of Pitolisant can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Pitolisant.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Pitolisant.Investigational
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Pitolisant.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Pitolisant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Pitolisant.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Pitolisant.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Pitolisant.Approved, Investigational
AripiprazoleThe serum concentration of Pitolisant can be increased when it is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Pitolisant.Approved, Investigational
ArtemetherThe serum concentration of Pitolisant can be increased when it is combined with Artemether.Approved
ArtenimolThe serum concentration of Pitolisant can be increased when it is combined with Artenimol.Approved, Investigational
AsenapineThe serum concentration of Pitolisant can be increased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Pitolisant.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Pitolisant.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Pitolisant.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Pitolisant.Approved
AtomoxetineThe serum concentration of Pitolisant can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Pitolisant can be increased when it is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Pitolisant.Approved
AvatrombopagThe serum concentration of Avatrombopag can be decreased when it is combined with Pitolisant.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Pitolisant.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pitolisant.Withdrawn
AzelastineThe serum concentration of Pitolisant can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Pitolisant.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pitolisant.Approved, Investigational
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Pitolisant.Investigational
BaricitinibThe serum concentration of Baricitinib can be decreased when it is combined with Pitolisant.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Pitolisant.Approved
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Pitolisant.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Pitolisant.Experimental
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Pitolisant.Approved, Investigational
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Pitolisant.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pitolisant.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Pitolisant.Approved
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Pitolisant.Approved, Illicit
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Pitolisant.Approved
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Pitolisant.Approved
Benzylpenicilloyl PolylysinePitolisant may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Pitolisant.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Pitolisant.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Pitolisant.Approved, Vet Approved
BetaxololThe serum concentration of Pitolisant can be increased when it is combined with Betaxolol.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Pitolisant.Experimental
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Pitolisant.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Pitolisant.Approved, Investigational
BicalutamideThe serum concentration of Pitolisant can be increased when it is combined with Bicalutamide.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Pitolisant.Approved, Investigational
BioallethrinThe serum concentration of Bioallethrin can be decreased when it is combined with Pitolisant.Approved, Experimental
BiperidenThe serum concentration of Pitolisant can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Pitolisant.Approved
BlonanserinThe serum concentration of Blonanserin can be decreased when it is combined with Pitolisant.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Pitolisant.Approved, Withdrawn
BortezomibThe serum concentration of Pitolisant can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Pitolisant.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Pitolisant.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Pitolisant.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Pitolisant.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be decreased when it is combined with Pitolisant.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Pitolisant.Approved
BrivaracetamThe serum concentration of Brivaracetam can be decreased when it is combined with Pitolisant.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pitolisant.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Pitolisant.Approved, Investigational
BrompheniramineThe serum concentration of Pitolisant can be increased when it is combined with Brompheniramine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pitolisant.Investigational
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Pitolisant.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pitolisant.Approved, Experimental
BufuralolThe metabolism of Bufuralol can be decreased when combined with Pitolisant.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Pitolisant.Experimental
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Pitolisant.Approved, Investigational
BuprenorphineThe serum concentration of Pitolisant can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Pitolisant can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Pitolisant.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Pitolisant.Approved, Investigational
ButriptylineThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Butriptyline.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Pitolisant.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Pitolisant.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Pitolisant.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Pitolisant.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Pitolisant.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Pitolisant.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Pitolisant.Approved
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Pitolisant.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Pitolisant.Approved
CarbamazepineThe serum concentration of Pitolisant can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pitolisant.Experimental, Investigational
CarbinoxamineThe serum concentration of Pitolisant can be increased when it is combined with Carbinoxamine.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Pitolisant.Approved, Investigational
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Pitolisant.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pitolisant.Approved, Vet Approved, Withdrawn
CarteololThe serum concentration of Pitolisant can be increased when it is combined with Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Pitolisant.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pitolisant.Experimental
CelecoxibThe serum concentration of Pitolisant can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Pitolisant.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Pitolisant.Approved
CerivastatinThe serum concentration of Pitolisant can be increased when it is combined with Cerivastatin.Approved, Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Pitolisant.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Pitolisant.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational
ChloroquineThe serum concentration of Pitolisant can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe serum concentration of Pitolisant can be increased when it is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Pitolisant.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Pitolisant can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Pitolisant.Approved
CholecalciferolThe serum concentration of Pitolisant can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pitolisant.Approved
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Pitolisant.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Pitolisant.Approved, Investigational
CimetidineThe serum concentration of Pitolisant can be increased when it is combined with Cimetidine.Approved, Investigational
Cimicifuga racemosaThe serum concentration of Pitolisant can be increased when it is combined with Cimicifuga racemosa.Approved, Experimental
CinacalcetThe serum concentration of Pitolisant can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Pitolisant.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Pitolisant.Approved, Investigational
CisaprideThe serum concentration of Pitolisant can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Pitolisant.Approved
CitalopramThe serum concentration of Pitolisant can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Pitolisant.Approved
ClemastineThe serum concentration of Pitolisant can be increased when it is combined with Clemastine.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Pitolisant.Approved, Investigational
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Pitolisant.Approved, Vet Approved
ClobazamThe serum concentration of Pitolisant can be increased when it is combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Pitolisant.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Pitolisant.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Pitolisant.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Pitolisant.Approved, Investigational
ClomipramineThe serum concentration of Pitolisant can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Pitolisant.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Pitolisant.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Pitolisant.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Pitolisant.Approved
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Pitolisant.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Pitolisant.Approved, Illicit
ClotrimazoleThe serum concentration of Pitolisant can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Pitolisant can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Pitolisant can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Pitolisant.Approved, Investigational
CocaineThe serum concentration of Pitolisant can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe serum concentration of Pitolisant can be increased when it is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Pitolisant.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Pitolisant.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Pitolisant.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Pitolisant.Approved, Investigational
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Pitolisant.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Pitolisant.Approved
CurcuminThe serum concentration of Pitolisant can be increased when it is combined with Curcumin.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Pitolisant.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Pitolisant.Approved, Investigational
CyclosporineThe serum concentration of Pitolisant can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Pitolisant can be increased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Pitolisant.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Pitolisant.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Pitolisant.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Pitolisant.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Pitolisant.Approved, Investigational
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Pitolisant.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Pitolisant.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Pitolisant.Approved, Investigational
DarifenacinThe serum concentration of Pitolisant can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Pitolisant.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Pitolisant.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Pitolisant.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Pitolisant.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Pitolisant.Approved, Investigational
DeferasiroxThe serum concentration of Pitolisant can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be decreased when it is combined with Pitolisant.Approved, Investigational
DelamanidThe serum concentration of Delamanid can be decreased when it is combined with Pitolisant.Approved, Investigational
DelavirdineThe serum concentration of Pitolisant can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe serum concentration of Pitolisant can be increased when it is combined with Deramciclane.Investigational
DesipramineThe serum concentration of Pitolisant can be increased when it is combined with Desipramine.Approved, Investigational
DesloratadineThe serum concentration of Pitolisant can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Pitolisant.Approved, Investigational
DeutetrabenazineThe serum concentration of Deutetrabenazine can be decreased when it is combined with Pitolisant.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Pitolisant.Approved
DexfenfluramineThe serum concentration of Pitolisant can be increased when it is combined with Dexfenfluramine.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe serum concentration of Dexlansoprazole can be decreased when it is combined with Pitolisant.Approved, Investigational
DexmedetomidineThe serum concentration of Pitolisant can be increased when it is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe serum concentration of Pitolisant can be increased when it is combined with Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe serum concentration of Pitolisant can be increased when it is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Pitolisant can be increased when it is combined with Dextromethorphan.Approved
DextropropoxypheneThe serum concentration of Pitolisant can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiacereinThe serum concentration of Pitolisant can be increased when it is combined with Diacerein.Approved, Investigational
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational, Vet Approved
DibenzepinThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Dibenzepin.Experimental
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Pitolisant.Approved, Vet Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Pitolisant.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Pitolisant.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Pitolisant.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Pitolisant.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pitolisant.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Pitolisant.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Pitolisant.Approved
Dihydro-alpha-ergocryptineThe serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Pitolisant.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Pitolisant.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Pitolisant.Approved, Investigational
DiltiazemThe serum concentration of Pitolisant can be increased when it is combined with Diltiazem.Approved, Investigational
DimetacrineThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Dimetacrine.Approved, Withdrawn
Dimethyl sulfoxideThe serum concentration of Pitolisant can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DiphenhydramineThe serum concentration of Pitolisant can be increased when it is combined with Diphenhydramine.Approved, Investigational
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Pitolisant.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Pitolisant.Approved
DisulfiramThe serum concentration of Pitolisant can be increased when it is combined with Disulfiram.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Pitolisant.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Pitolisant.Approved, Investigational
DolasetronThe serum concentration of Pitolisant can be increased when it is combined with Dolasetron.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Pitolisant.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Pitolisant.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Pitolisant.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Pitolisant.Approved
DosulepinThe serum concentration of Pitolisant can be increased when it is combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Pitolisant.Approved
DoxepinThe serum concentration of Pitolisant can be increased when it is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Pitolisant can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Pitolisant can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Pitolisant.Approved, Illicit
DronedaroneThe serum concentration of Pitolisant can be increased when it is combined with Dronedarone.Approved
DroperidolThe risk or severity of QTc prolongation can be increased when Droperidol is combined with Pitolisant.Approved, Vet Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Pitolisant.Withdrawn
DuloxetineThe serum concentration of Pitolisant can be increased when it is combined with Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Pitolisant.Approved, Investigational
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pitolisant.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Pitolisant.Investigational
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Pitolisant.Approved
EfavirenzThe serum concentration of Pitolisant can be increased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be decreased when it is combined with Pitolisant.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Pitolisant.Approved, Investigational
EliglustatThe serum concentration of Pitolisant can be increased when it is combined with Eliglustat.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Pitolisant.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Pitolisant.Approved, Vet Approved
EnasidenibThe serum concentration of Pitolisant can be increased when it is combined with Enasidenib.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Pitolisant.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Pitolisant.Investigational
EntacaponeThe serum concentration of Pitolisant can be increased when it is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Pitolisant can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Pitolisant can be increased when it is combined with Epinastine.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Pitolisant.Approved
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Pitolisant.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Pitolisant.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Pitolisant.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Pitolisant.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Pitolisant.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Pitolisant.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be decreased when it is combined with Pitolisant.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
EscitalopramThe serum concentration of Pitolisant can be increased when it is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Pitolisant.Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Pitolisant.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Pitolisant.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Pitolisant.Approved, Investigational
EstriolThe serum concentration of Estriol can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Pitolisant.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Pitolisant.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Pitolisant.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Pitolisant.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pitolisant.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Pitolisant.Approved
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Pitolisant.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Pitolisant.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Pitolisant.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Pitolisant.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be decreased when it is combined with Pitolisant.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pitolisant.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pitolisant.Approved, Investigational
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Pitolisant.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Pitolisant.Approved
EtoricoxibThe serum concentration of Pitolisant can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Pitolisant.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pitolisant.Investigational, Nutraceutical
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Pitolisant.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Pitolisant.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Pitolisant.Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Pitolisant.Approved
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Pitolisant.Approved, Investigational
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Pitolisant.Approved
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Pitolisant.Experimental
FelodipineThe serum concentration of Pitolisant can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pitolisant.Approved
FenfluramineThe serum concentration of Pitolisant can be increased when it is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Pitolisant.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pitolisant.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pitolisant.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Pitolisant.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Pitolisant.Experimental
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Pitolisant.Approved
FexofenadineThe serum concentration of Pitolisant can be increased when it is combined with Fexofenadine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Pitolisant.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Pitolisant.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Pitolisant.Approved, Investigational
FlecainideThe serum concentration of Pitolisant can be increased when it is combined with Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Pitolisant.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pitolisant.Approved, Withdrawn
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be decreased when it is combined with Pitolisant.Approved
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Pitolisant.Approved, Investigational
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Pitolisant.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Pitolisant.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Pitolisant.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Pitolisant.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Pitolisant.Experimental
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Pitolisant.Approved, Investigational
FluoxetineThe serum concentration of Pitolisant can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe serum concentration of Pitolisant can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pitolisant.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Pitolisant.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Pitolisant.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be decreased when it is combined with Pitolisant.Approved
FluvastatinThe serum concentration of Pitolisant can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Pitolisant can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Pitolisant.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Pitolisant.Approved
FosaprepitantThe serum concentration of Pitolisant can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe serum concentration of Fosnetupitant can be decreased when it is combined with Pitolisant.Approved
FosphenytoinThe serum concentration of Pitolisant can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe serum concentration of Fostamatinib can be decreased when it is combined with Pitolisant.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Pitolisant.Approved, Investigational
Fusidic AcidThe serum concentration of Pitolisant can be increased when it is combined with Fusidic Acid.Approved, Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Pitolisant.Approved
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Pitolisant.Approved, Investigational
GefitinibThe serum concentration of Pitolisant can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Pitolisant.Approved
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Pitolisant.Approved
GepefrineGepefrine may decrease the sedative activities of Pitolisant.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Pitolisant.Approved, Investigational
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Pitolisant.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Pitolisant.Approved
Glycerol PhenylbutyrateThe serum concentration of Pitolisant can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GranisetronThe serum concentration of Pitolisant can be increased when it is combined with Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Pitolisant.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Pitolisant.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Pitolisant.Experimental
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Pitolisant.Approved, Investigational
HalofantrineThe serum concentration of Pitolisant can be increased when it is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Pitolisant can be increased when it is combined with Haloperidol.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Pitolisant.Approved, Vet Approved
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Pitolisant.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Pitolisant.Investigational
HistamineThe serum concentration of Pitolisant can be increased when it is combined with Histamine.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pitolisant.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Pitolisant.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Pitolisant.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Pitolisant.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Pitolisant.Approved
HydroxychloroquineThe serum concentration of Pitolisant can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Pitolisant.Approved, Investigational
HydroxyureaThe serum concentration of Pitolisant can be increased when it is combined with Hydroxyurea.Approved
HydroxyzineThe serum concentration of Pitolisant can be increased when it is combined with Hydroxyzine.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Pitolisant.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Pitolisant.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Pitolisant.Withdrawn
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Pitolisant.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Pitolisant.Approved, Investigational
IcotinibThe serum concentration of Icotinib can be decreased when it is combined with Pitolisant.Approved, Investigational
IdarubicinThe serum concentration of Pitolisant can be increased when it is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Pitolisant.Approved
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Pitolisant.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Pitolisant.Approved
ImatinibThe serum concentration of Pitolisant can be increased when it is combined with Imatinib.Approved
ImidafenacinThe serum concentration of Imidafenacin can be decreased when it is combined with Pitolisant.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Pitolisant.Experimental
ImipramineThe serum concentration of Pitolisant can be increased when it is combined with Imipramine.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Pitolisant.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Pitolisant.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Pitolisant.Approved
IndinavirThe serum concentration of Pitolisant can be increased when it is combined with Indinavir.Approved
IndisulamThe serum concentration of Pitolisant can be increased when it is combined with Indisulam.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Pitolisant.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Pitolisant.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pitolisant.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Pitolisant.Approved, Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Pitolisant.Approved
IpecacThe serum concentration of Ipecac can be decreased when it is combined with Pitolisant.Approved, Withdrawn
IpratropiumThe serum concentration of Ipratropium bromide can be decreased when it is combined with Pitolisant.Approved
IprindoleThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Iprindole.Experimental
IrbesartanThe serum concentration of Pitolisant can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Pitolisant.Approved, Investigational
IsavuconazoleThe serum concentration of Pitolisant can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Pitolisant.Approved, Investigational
IsofluraneThe serum concentration of Isoflurane can be decreased when it is combined with Pitolisant.Approved, Vet Approved
IsoniazidThe serum concentration of Pitolisant can be increased when it is combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Pitolisant.Approved, Investigational
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Pitolisant.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pitolisant.Withdrawn
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Pitolisant.Approved, Investigational
ItraconazoleThe serum concentration of Pitolisant can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Pitolisant.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Pitolisant.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Pitolisant.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Pitolisant.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pitolisant.Experimental
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Pitolisant.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Pitolisant.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Pitolisant.Approved, Investigational
KetoconazoleThe serum concentration of Pitolisant can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pitolisant.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pitolisant.Approved
LabetalolThe serum concentration of Pitolisant can be increased when it is combined with Labetalol.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Pitolisant.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Pitolisant.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Pitolisant.Approved, Investigational
LansoprazoleThe serum concentration of Pitolisant can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Pitolisant.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Pitolisant.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Pitolisant.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Pitolisant.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Pitolisant.Approved, Investigational
LercanidipineThe serum concentration of Pitolisant can be increased when it is combined with Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be decreased when it is combined with Pitolisant.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Pitolisant.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Pitolisant.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Pitolisant.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Pitolisant.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Pitolisant.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Pitolisant.Approved, Investigational
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Pitolisant.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Pitolisant.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Pitolisant.Approved, Investigational
LevosalbutamolThe serum concentration of Pitolisant can be increased when it is combined with Levosalbutamol.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Pitolisant.Approved
LidocaineThe serum concentration of Pitolisant can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Pitolisant.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Pitolisant.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pitolisant.Investigational
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Pitolisant.Approved, Investigational
LofepramineThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Pitolisant.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Pitolisant.Approved, Investigational
LomustineThe serum concentration of Pitolisant can be increased when it is combined with Lomustine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Pitolisant.Experimental
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Pitolisant.Approved
LopinavirThe serum concentration of Pitolisant can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Pitolisant can be increased when it is combined with Loratadine.Approved, Investigational
LorcaserinThe serum concentration of Pitolisant can be increased when it is combined with Lorcaserin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pitolisant.Approved, Investigational
LorpiprazoleThe serum concentration of Pitolisant can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Pitolisant.Approved
LovastatinThe serum concentration of Pitolisant can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pitolisant.Approved, Investigational
LuliconazoleThe serum concentration of Pitolisant can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pitolisant can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Pitolisant can be increased when it is combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pitolisant.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Pitolisant.Approved, Investigational
MacimorelinThe serum concentration of Macimorelin can be decreased when it is combined with Pitolisant.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Pitolisant.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pitolisant.Approved
MalathionThe serum concentration of Malathion can be decreased when it is combined with Pitolisant.Approved, Investigational
ManidipineThe serum concentration of Pitolisant can be increased when it is combined with Manidipine.Approved, Investigational
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Pitolisant.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Pitolisant.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Pitolisant.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pitolisant.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Pitolisant.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pitolisant.Approved, Vet Approved
Medical CannabisThe serum concentration of Medical Cannabis can be decreased when it is combined with Pitolisant.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Pitolisant.Approved, Investigational
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pitolisant.Approved
MefloquineThe serum concentration of Pitolisant can be increased when it is combined with Mefloquine.Approved, Investigational
MelitracenThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Melitracen.Experimental, Investigational
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Pitolisant.Approved, Vet Approved
MelperoneThe serum concentration of Pitolisant can be increased when it is combined with Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Pitolisant.Investigational
MephentermineMephentermine may decrease the sedative activities of Pitolisant.Approved
MephenytoinThe serum concentration of Mephenytoin can be decreased when it is combined with Pitolisant.Investigational, Withdrawn
MepyramineThe serum concentration of Pitolisant can be increased when it is combined with Mepyramine.Approved, Vet Approved
MequitazineThe metabolism of Mequitazine can be decreased when combined with Pitolisant.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pitolisant.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Pitolisant.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pitolisant.Approved, Investigational, Withdrawn
MethadoneThe serum concentration of Pitolisant can be increased when it is combined with Methadone.Approved
MethamphetamineThe serum concentration of Pitolisant can be increased when it is combined with Methamphetamine.Approved, Illicit
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Pitolisant.Illicit, Withdrawn
MethazolamideThe serum concentration of Pitolisant can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Pitolisant can be increased when it is combined with Methimazole.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Pitolisant.Approved
MethotrimeprazineThe serum concentration of Pitolisant can be increased when it is combined with Methotrimeprazine.Approved, Investigational
MethoxsalenThe serum concentration of Pitolisant can be increased when it is combined with Methoxsalen.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Pitolisant.Experimental
MethylnaltrexoneThe serum concentration of Pitolisant can be increased when it is combined with Methylnaltrexone.Approved
MethylphenidateThe serum concentration of Pitolisant can be increased when it is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be decreased when it is combined with Pitolisant.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Pitolisant.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Pitolisant.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Pitolisant.Approved, Illicit, Withdrawn
MetoclopramideThe serum concentration of Pitolisant can be increased when it is combined with Metoclopramide.Approved, Investigational
MetoprololThe serum concentration of Pitolisant can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Pitolisant.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Pitolisant.Approved, Investigational
MianserinThe serum concentration of Pitolisant can be increased when it is combined with Mianserin.Approved, Investigational
MibefradilThe serum concentration of Pitolisant can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Pitolisant can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Pitolisant.Approved, Illicit
MidecamycinThe serum concentration of Midecamycin can be decreased when it is combined with Pitolisant.Approved
MidodrineThe serum concentration of Pitolisant can be increased when it is combined with Midodrine.Approved
MidomafetamineMidomafetamine may decrease the sedative activities of Pitolisant.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of Pitolisant can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Pitolisant can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Pitolisant.Approved
MirabegronThe serum concentration of Pitolisant can be increased when it is combined with Mirabegron.Approved
MirtazapineThe serum concentration of Pitolisant can be increased when it is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Pitolisant can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Pitolisant.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pitolisant.Investigational
MMDAMMDA may decrease the sedative activities of Pitolisant.Experimental, Illicit
MoclobemideThe serum concentration of Pitolisant can be increased when it is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Pitolisant.Approved, Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Pitolisant.Experimental
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Pitolisant.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Pitolisant.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pitolisant.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Pitolisant.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pitolisant.Approved
NabiximolsThe serum concentration of Nabiximols can be decreased when it is combined with Pitolisant.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pitolisant.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Pitolisant.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pitolisant.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pitolisant.Approved
NaloxegolThe serum concentration of Pitolisant can be increased when it is combined with Naloxegol.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Pitolisant.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pitolisant.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Pitolisant.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Pitolisant.Approved, Investigational
NefazodoneThe serum concentration of Pitolisant can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Pitolisant can be increased when it is combined with Nelfinavir.Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pitolisant.Approved, Investigational
NeratinibThe serum concentration of Neratinib can be decreased when it is combined with Pitolisant.Approved, Investigational
NetupitantThe serum concentration of Pitolisant can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Pitolisant can be decreased when it is combined with Nevirapine.Approved
NiacinThe serum concentration of Pitolisant can be increased when it is combined with Niacin.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of Pitolisant can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Pitolisant.Approved, Investigational
NicotinamideThe serum concentration of Pitolisant can be increased when it is combined with Nicotinamide.Approved, Investigational
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Pitolisant.Approved
NifedipineThe serum concentration of Pitolisant can be increased when it is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Pitolisant.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pitolisant.Approved
NilotinibThe serum concentration of Pitolisant can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Pitolisant.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pitolisant.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Pitolisant.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Pitolisant.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Pitolisant.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Pitolisant.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Pitolisant.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pitolisant.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Pitolisant.Approved, Investigational, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Pitolisant.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Pitolisant.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Pitolisant.Approved
NortriptylineThe serum concentration of Pitolisant can be increased when it is combined with Nortriptyline.Approved
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Pitolisant.Investigational
OlanzapineThe serum concentration of Pitolisant can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Pitolisant.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Pitolisant.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pitolisant.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Pitolisant.Approved, Investigational
OmeprazoleThe serum concentration of Pitolisant can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Pitolisant can be increased when it is combined with Ondansetron.Approved
OpipramolThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Opipramol.Investigational
OpiumThe serum concentration of Opium can be decreased when it is combined with Pitolisant.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Pitolisant.Vet Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Pitolisant.Approved
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Pitolisant.Approved
OspemifeneThe serum concentration of Pitolisant can be increased when it is combined with Ospemifene.Approved, Investigational
OxaliplatinThe risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Pitolisant.Approved, Investigational
OxamniquineThe serum concentration of Pitolisant can be increased when it is combined with Oxamniquine.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pitolisant.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Pitolisant.Approved
OxprenololThe serum concentration of Pitolisant can be increased when it is combined with Oxprenolol.Approved
OxybutyninThe serum concentration of Pitolisant can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational
OxymetholoneThe serum concentration of Pitolisant can be increased when it is combined with Oxymetholone.Approved, Illicit
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pitolisant.Approved, Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Pitolisant.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Pitolisant.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Pitolisant.Experimental, Nutraceutical
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Pitolisant.Approved, Investigational
PanobinostatThe serum concentration of Pitolisant can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Pitolisant.Approved
PapaverineThe risk or severity of QTc prolongation can be increased when Papaverine is combined with Pitolisant.Approved, Investigational
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Pitolisant.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Pitolisant.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Pitolisant.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Pitolisant.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Pitolisant.Approved, Investigational
ParoxetineThe serum concentration of Pitolisant can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Pitolisant.Approved, Investigational
PazopanibThe serum concentration of Pitolisant can be increased when it is combined with Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Pitolisant can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe serum concentration of Pitolisant can be increased when it is combined with Pentamidine.Approved, Investigational
PentobarbitalThe serum concentration of Pitolisant can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Pitolisant.Approved
PergolideThe serum concentration of Pitolisant can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Pitolisant can be increased when it is combined with Perhexiline.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Pitolisant.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be decreased when it is combined with Pitolisant.Approved
PerphenazineThe serum concentration of Pitolisant can be increased when it is combined with Perphenazine.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Pitolisant.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Pitolisant.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Pitolisant.Approved, Investigational, Withdrawn
PheniramineThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Pheniramine.Approved
PhenobarbitalThe serum concentration of Pitolisant can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Pitolisant.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Pitolisant.Approved, Investigational
PhentermineThe serum concentration of Pitolisant can be increased when it is combined with Phentermine.Approved, Illicit
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pitolisant.Approved, Vet Approved
Phenylbutyric acidThe serum concentration of Pitolisant can be increased when it is combined with Phenylbutyric acid.Approved, Investigational
PhenytoinThe serum concentration of Pitolisant can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Pitolisant.Approved, Investigational
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Pitolisant.Approved, Investigational
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Pitolisant.Approved, Investigational
PimozideThe serum concentration of Pitolisant can be increased when it is combined with Pimozide.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Pitolisant.Approved
PindololThe serum concentration of Pitolisant can be increased when it is combined with Pindolol.Approved, Investigational
PioglitazoneThe serum concentration of Pitolisant can be increased when it is combined with Pioglitazone.Approved, Investigational
PiperaquineThe serum concentration of Piperaquine can be decreased when it is combined with Pitolisant.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Pitolisant.Approved, Vet Approved
PipotiazineThe serum concentration of Pitolisant can be increased when it is combined with Pipotiazine.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pitolisant.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pitolisant.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Pitolisant.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Pitolisant.Approved
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Pitolisant.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Pitolisant.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Pitolisant.Approved, Investigational
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Pitolisant.Experimental, Investigational
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Pitolisant.Approved, Investigational, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Pitolisant.Approved
PravastatinThe serum concentration of Pitolisant can be increased when it is combined with Pravastatin.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Pitolisant.Approved, Illicit
PraziquantelThe serum concentration of Pitolisant can be increased when it is combined with Praziquantel.Approved, Investigational, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Pitolisant.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Pitolisant.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Pitolisant.Approved, Vet Approved
PrimaquineThe serum concentration of Pitolisant can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Pitolisant can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Probucol is combined with Pitolisant.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Pitolisant.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Pitolisant.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Pitolisant.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Pitolisant.Experimental
ProguanilThe serum concentration of Pitolisant can be increased when it is combined with Proguanil.Approved
PromazineThe serum concentration of Pitolisant can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Pitolisant can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pitolisant.Approved, Investigational
PropafenoneThe serum concentration of Pitolisant can be increased when it is combined with Propafenone.Approved
PropiverineThe serum concentration of Propiverine can be decreased when it is combined with Pitolisant.Approved, Investigational
PropofolThe serum concentration of Pitolisant can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Pitolisant can be increased when it is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Pitolisant.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Pitolisant.Experimental
ProtriptylineThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Protriptyline.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Pitolisant.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Pitolisant.Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Pitolisant.Approved, Investigational
PyrimethamineThe serum concentration of Pitolisant can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Pitolisant.Approved, Illicit
QuetiapineThe serum concentration of Pitolisant can be increased when it is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Pitolisant.Approved, Investigational
QuinidineThe serum concentration of Pitolisant can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Pitolisant can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Pitolisant can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Pitolisant.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Pitolisant.Approved, Investigational
RanitidineThe serum concentration of Pitolisant can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Pitolisant can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Pitolisant can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Pitolisant.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Pitolisant.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Pitolisant.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Pitolisant.Investigational
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Pitolisant.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pitolisant.Approved, Experimental, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Pitolisant.Approved
RheinThe serum concentration of Pitolisant can be increased when it is combined with Rhein.Experimental
RifabutinThe serum concentration of Pitolisant can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Pitolisant can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Pitolisant can be decreased when it is combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Pitolisant.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Pitolisant.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Pitolisant.Approved
RisperidoneThe serum concentration of Pitolisant can be increased when it is combined with Risperidone.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Pitolisant.Investigational
RitonavirThe serum concentration of Pitolisant can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Pitolisant.Approved
RivastigmineThe serum concentration of Pitolisant can be increased when it is combined with Rivastigmine.Approved, Investigational
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Pitolisant.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Pitolisant can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Pitolisant.Approved, Investigational
RopiniroleThe serum concentration of Pitolisant can be increased when it is combined with Ropinirole.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Pitolisant.Approved
RosiglitazoneThe serum concentration of Pitolisant can be increased when it is combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Pitolisant.Approved
RotigotineThe serum concentration of Pitolisant can be increased when it is combined with Rotigotine.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Pitolisant.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Pitolisant can be increased when it is combined with Rucaparib.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be decreased when it is combined with Pitolisant.Approved
RutinThe serum concentration of Pitolisant can be increased when it is combined with Rutin.Experimental, Investigational
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Pitolisant.Approved
SafinamideThe serum concentration of Safinamide can be decreased when it is combined with Pitolisant.Approved, Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pitolisant.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Pitolisant.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pitolisant.Approved
SaquinavirThe serum concentration of Pitolisant can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Pitolisant.Approved
SelegilineThe serum concentration of Pitolisant can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Pitolisant.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Pitolisant.Investigational
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Pitolisant.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pitolisant.Investigational
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Pitolisant.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Pitolisant can be increased when it is combined with Sertraline.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Pitolisant.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Pitolisant can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Pitolisant.Approved
SiltuximabThe serum concentration of Pitolisant can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Pitolisant can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Pitolisant can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Pitolisant.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Pitolisant.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Pitolisant.Approved
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Pitolisant.Approved
SomatostatinThe serum concentration of Somatostatin can be decreased when it is combined with Pitolisant.Approved, Investigational
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Pitolisant.Approved, Investigational
SorafenibThe serum concentration of Pitolisant can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Pitolisant.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Pitolisant.Approved, Investigational
SparteineThe serum concentration of Pitolisant can be increased when it is combined with Sparteine.Experimental
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Pitolisant.Experimental
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Pitolisant.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Pitolisant.Investigational
St. John's WortThe serum concentration of Pitolisant can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be decreased when it is combined with Pitolisant.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be decreased when it is combined with Pitolisant.Experimental
StiripentolThe serum concentration of Pitolisant can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Pitolisant.Approved, Investigational
SulconazoleThe serum concentration of Pitolisant can be increased when it is combined with Sulconazole.Approved
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Pitolisant.Approved
SulfanilamideThe serum concentration of Pitolisant can be increased when it is combined with Sulfanilamide.Approved
SulfaphenazoleThe serum concentration of Pitolisant can be increased when it is combined with Sulfaphenazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pitolisant.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Pitolisant.Approved
SulfisoxazoleThe metabolism of Pitolisant can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pitolisant.Approved, Investigational
SulpirideThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Pitolisant.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Sultopride is combined with Pitolisant.Experimental
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Pitolisant.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pitolisant.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Pitolisant.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Pitolisant.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Pitolisant.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Pitolisant.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Pitolisant.Approved, Investigational
TamoxifenThe serum concentration of Pitolisant can be increased when it is combined with Tamoxifen.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Pitolisant.Approved, Investigational
TapentadolThe serum concentration of Pitolisant can be increased when it is combined with Tapentadol.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pitolisant.Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Pitolisant.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Pitolisant.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Pitolisant.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Pitolisant.Approved, Investigational
TegaserodThe serum concentration of Pitolisant can be increased when it is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Pitolisant.Approved, Withdrawn
TelithromycinThe serum concentration of Pitolisant can be increased when it is combined with Telithromycin.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Pitolisant.Approved, Investigational
TemsirolimusThe serum concentration of Pitolisant can be increased when it is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Pitolisant.Experimental
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Pitolisant.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pitolisant.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Pitolisant.Vet Approved
TerbinafineThe serum concentration of Pitolisant can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Pitolisant can be increased when it is combined with Terfenadine.Approved, Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pitolisant.Approved
TerlipressinThe risk or severity of QTc prolongation can be increased when Terlipressin is combined with Pitolisant.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Terodiline is combined with Pitolisant.Experimental
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Pitolisant.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Pitolisant.Approved, Investigational
Testosterone cypionateThe serum concentration of Testosterone cypionate can be decreased when it is combined with Pitolisant.Approved
Testosterone enanthateThe serum concentration of Testosterone enanthate can be decreased when it is combined with Pitolisant.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be decreased when it is combined with Pitolisant.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Testosterone undecanoate can be decreased when it is combined with Pitolisant.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Pitolisant.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Pitolisant.Approved, Vet Approved
TezacaftorThe serum concentration of Tezacaftor can be decreased when it is combined with Pitolisant.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Pitolisant.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pitolisant.Approved, Withdrawn
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Pitolisant.Approved, Investigational
ThiothixeneThe serum concentration of Pitolisant can be increased when it is combined with Thiothixene.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Pitolisant.Approved, Investigational
TianeptineThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Tianeptine.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pitolisant.Approved
TicagrelorThe serum concentration of Pitolisant can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Pitolisant can be increased when it is combined with Ticlopidine.Approved
TimololThe serum concentration of Pitolisant can be increased when it is combined with Timolol.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Pitolisant.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pitolisant.Investigational
TioconazoleThe serum concentration of Pitolisant can be increased when it is combined with Tioconazole.Approved
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Pitolisant.Approved
TipranavirThe serum concentration of Pitolisant can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Pitolisant can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe serum concentration of Tocofersolan can be decreased when it is combined with Pitolisant.Approved
TocopherolThe serum concentration of Tocopherol can be decreased when it is combined with Pitolisant.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Pitolisant.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pitolisant.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pitolisant.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Pitolisant.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Pitolisant.Approved
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Pitolisant.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Pitolisant.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Pitolisant.Approved, Investigational
TramadolThe serum concentration of Pitolisant can be increased when it is combined with Tramadol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Pitolisant.Approved, Investigational
TranylcypromineThe serum concentration of Pitolisant can be increased when it is combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Pitolisant.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Pitolisant.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Pitolisant.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Pitolisant.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Pitolisant.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pitolisant.Experimental
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Pitolisant.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Pitolisant.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Pitolisant.Approved
TripelennamineThe serum concentration of Pitolisant can be increased when it is combined with Tripelennamine.Approved, Vet Approved
TriprolidineThe serum concentration of Pitolisant can be increased when it is combined with Triprolidine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Pitolisant.Investigational
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Pitolisant.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Pitolisant.Approved
TrospiumThe serum concentration of Pitolisant can be increased when it is combined with Trospium.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Pitolisant.Approved, Investigational, Nutraceutical
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Pitolisant.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Pitolisant.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Pitolisant.Approved
ValbenazineThe serum concentration of Valbenazine can be decreased when it is combined with Pitolisant.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Pitolisant.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Pitolisant.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Pitolisant.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Pitolisant.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Pitolisant.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Pitolisant.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Pitolisant.Approved, Investigational
VemurafenibThe serum concentration of Pitolisant can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Pitolisant.Approved, Investigational
VenlafaxineThe serum concentration of Pitolisant can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Pitolisant can be increased when it is combined with Verapamil.Approved
VernakalantThe serum concentration of Pitolisant can be increased when it is combined with Vernakalant.Approved, Investigational
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Pitolisant.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Pitolisant.Approved
VilazodoneThe serum concentration of Pitolisant can be increased when it is combined with Vilazodone.Approved
VinblastineThe serum concentration of Pitolisant can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Pitolisant.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Pitolisant.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be decreased when it is combined with Pitolisant.Approved, Investigational
VinorelbineThe serum concentration of Pitolisant can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Pitolisant.Approved, Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Pitolisant.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Pitolisant.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Pitolisant.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Pitolisant.Approved
YohimbineThe serum concentration of Pitolisant can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe serum concentration of Pitolisant can be increased when it is combined with Zafirlukast.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Pitolisant.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Pitolisant.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pitolisant.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Pitolisant.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Pitolisant.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Pitolisant can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Pitolisant.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Pitolisant.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Pitolisant.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Pitolisant.Approved
ZotepineThe serum concentration of Zotepine can be decreased when it is combined with Pitolisant.Approved, Investigational, Withdrawn
ZucapsaicinThe serum concentration of Pitolisant can be increased when it is combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Pitolisant.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Calik MW: Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nat Sci Sleep. 2017 Apr 26;9:127-133. doi: 10.2147/NSS.S103462. eCollection 2017. [PubMed:28490912]
  2. Inocente C, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimao R, Lin JS, Franco P: Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012 Mar-Apr;35(2):55-60. doi: 10.1097/WNF.0b013e318246879d. [PubMed:22356925]
  3. Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC: Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013 Nov;12(11):1068-75. doi: 10.1016/S1474-4422(13)70225-4. Epub 2013 Oct 7. [PubMed:24107292]
  4. Schwartz JC: The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011 Jun;163(4):713-21. doi: 10.1111/j.1476-5381.2011.01286.x. [PubMed:21615387]
  5. Wakix, INN-Pitolisant - European Medicines Agency - Europa EU [Link]
  6. Wakix, INN-pitolisant - European Medicines Agency - Europa EU: Assessment report [Link]
External Links
ChemSpider
8123714
BindingDB
50247053
ChEBI
134709
ChEMBL
CHEMBL462605
Wikipedia
Pitolisant
ATC Codes
N07XX11 — Pitolisant

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentDrug Abuse / Healthy Volunteers1
1CompletedTreatmentImpaired Renal Function1
2CompletedTreatmentExcessive Daytime Sleepiness / Obstructive Sleep Apnoea (OSA)1
2CompletedTreatmentExcessive Daytime Sleepiness / Parkinson's Disease (PD)1
2CompletedTreatmentSchizophrenic Disorders1
2RecruitingTreatmentNarcolepsy With Cataplexy / Narcolepsy Without Cataplexy1
2WithdrawnTreatmentAlcohol Abuse, Nervous System1
3CompletedTreatmentCataplexy / Excessive Daytime Sleepiness / Narcolepsy1
3CompletedTreatmentCataplexy / Excessive Daytime Sleepiness / Narcolepsy / Sleep disorders and disturbances1
3CompletedTreatmentCataplexy / Narcolepsy1
3CompletedTreatmentExcessive Daytime Sleepiness / Narcolepsy With Cataplexy1
3CompletedTreatmentExcessive Daytime Sleepiness / Obstructive Sleep Apnea (OSA)3
3CompletedTreatmentNarcolepsy1
3CompletedTreatmentParkinson's Disease (PD)2
3CompletedTreatmentTreatment of Excessive Daytime Sleepiness in Narcolepsy1
3WithdrawnTreatmentExcessive Daytime Sleepiness / Obstructive Sleep Apnea (OSA)1
Not AvailableAvailableNot AvailableNarcolepsy With Cataplexy / Narcolepsy Without Cataplexy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral18 mg
Tablet, film coatedOral4.5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00142 mg/mLALOGPS
logP4.47ALOGPS
logP4.12ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity86.81 m3·mol-1ChemAxon
Polarizability35.5 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Chlorobenzenes
Alternative Parents
Piperidines / Aryl chlorides / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Chlorobenzene / Aryl chloride / Aryl halide / Piperidine / Tertiary amine / Tertiary aliphatic amine / Azacycle / Ether / Dialkyl ether / Organoheterocyclic compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Inverse agonist
Curator comments
Pitolisant acts as a high-affinity competitive antagonist (Ki 0.16 nM) and as an inverse agonist (EC50 1.5 nM) at the human histamine H3 receptor subtype.
General Function
Histamine receptor activity
Specific Function
The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive a...
Gene Name
HRH3
Uniprot ID
Q9Y5N1
Uniprot Name
Histamine H3 receptor
Molecular Weight
48670.81 Da
References
  1. Schwartz JC: The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011 Jun;163(4):713-21. doi: 10.1111/j.1476-5381.2011.01286.x. [PubMed:21615387]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Blocker
Curator comments
Pitolisant blocked hERG channel with an IC50 exceeding therapeutic concentrations and induced a slight QTc prolongation in dogs.
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
Curator comments
Induction of CYP3A4 by pitolisant was observed in vitro.
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
Pitolisant is an inhibitor of CYP2D6 with moderate potency (IC50 = 2.6 μM).
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
Curator comments
Inhibition of CYP1A2 by pitolisant was observed in vitro.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
Curator comments
Inhibition of CYP2B6 by pitolisant was observed in vitro.
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
Pitolisant shows greater than 50% inhibition towards OCT1 (organic cation transporters 1) at 1.33 μM, and the extrapolated IC50 of pitolisant is 0.795 μM.
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da

Drug created on October 17, 2016 15:30 / Updated on July 02, 2018 19:26